Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis

Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations. Agreement advances Teva’s Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations. Agreement reflects both companies’ commitment to broadening access to biologic medicines. TEL AVIV, Israel and ZUG, Switzerland, July 09, 2026 […]